PRS5 Predictors Of Willingness To Quit Cigarette Smoking In A Cohort Of Adults In India  by Jadav, S. & Sansgiry, S.S.
A232 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
PRS5  
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ADULTS IN INDIA  
Jadav S, Sansgiry SS 
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OBJECTIVES: With 182 million smokers living in India, cigarette smoking is a 
serious public health problem associated with severe morbidities and significant 
economic burden. As willingness to quit smoking has been found to be 
associated with smoking cessation; the main objective of the study was to 
examine the predictors of willingness to quit smoking in a cohort of adults in 
India. METHODS: A cross-sectional study was conducted among adults aged ≥18 
years in metropolitan cities in India. Participants completed self-reported 
questionnaire about socio-demographic variables, smoking status, smoking 
status of peers, history of past quit attempts, addiction level and attitudes 
towards smoking. Study cohort consisted of individuals who smoked at least one 
cigarette in the past 30 days. Outcome variable was willingness to quit smoking. 
Variables that were found significant (p<0.05) in bivariate analyses were included 
in multivariate logistic regression models to determine predictors of willingness 
to quit smoking. RESULTS: Out of 761 participants, 469 respondents (61.6 %) were 
smokers and 253 (54%) of smokers were willing to quit smoking. Regression 
showed that higher willingness to quit smoking was associated with group of age 
40-49 years (OR:2.41, 95%CI: 1.19-4.90), religion Muslim (OR:0.46, 95%CI: 0.25-0.83) 
or Christian ( OR: 0.41, 95%CI: 0.22-0.76), close friend (OR:2.23, 95%CI: 1.40-3.57) 
and siblings (OR:3.06, 95%CI: 1.95 - 4.78) being non-smoker , higher number of 
smoking friends (OR:1.85, 95%CI: 1.05-3.24) and previously tried to quit smoking 3 
times (OR:2.30, 95% CI: 1.36 - 3.87) or more than 3 times (OR:22.89, 95%CI: 5.27-
99.32). All reported values are statistically significant (p<0.05). CONCLUSIONS: 
Our study identified significant predictors of willingness to quit smoking among 
a cohort of adults in India. Intervention strategies should be developed 
considering targeted programs to address opportunities for individuals willing to 
quit smoking.  
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OBJECTIVES: Presence of underlying medical conditions is believed to increase 
risk of pneumococcal disease (PD) across all age groups. However, excess risks of 
PD attributable to specific conditions are not well known in children or adults, 
nor are condition-specific attributable economic costs. METHODS: Using health 
care claims information from ~80 million persons annually, plan members 
during 2007-2010 were stratified into subgroups based on presence of selected 
“at-risk” chronic conditions (eg, heart, lung, and liver disease, asthma, diabetes) 
and “high-risk” immunocompromising conditions (eg, malignancies, HIV, 
chronic renal disease). At-risk and high-risk conditions, and episodes of invasive 
pneumococcal disease (IPD) and all-cause pneumonia (PNE), were identified via 
diagnosis, procedure, and drug codes. Annual PD rates and PD-attributable 
health care costs (2010US$) among at-risk and high-risk persons versus age-
matched healthy counterparts were compared using incidence rate ratios (IRR) 
and cost ratios; corresponding 95% CIs were estimated using Poisson regression 
and nonparametric bootstrapping. RESULTS: Annual rates of IPD and PNE were 
consistently higher among at-risk persons (IRR=3.8 [95% CI 3.5-4.0] and 4.5 [4.5-
4.6]) and high-risk persons (IRR=9.3 [8.6-10.0] and 8.2 [8.2-8.3]) versus their 
healthy counterparts. Rates were notably high for at-risk persons with asthma 
(IRR=3.2 [2.8-3.7] and 4.4 [4.4-4.5]), diabetes (IRR=3.8 [3.5-4.2] and 4.6 [4.5-4.6]), or 
≥2 at-risk conditions (IRR=8.5 [7.8-9.2] and 10.6 [10.6-10.7]). Annual PD-
attributable health care costs totaled $56.1 million per 100,000 at-risk person-
years and $118.9 million per 100,000 high-risk person-years, which were 5.2 [5.1-
5.2] and 11.0 [10.9-11.0] times higher than corresponding costs for healthy 
persons. CONCLUSIONS: Rates and costs of PD are substantially higher among 
persons with certain chronic and immunocompromising conditions versus those 
without any such conditions. Rates and costs for persons with asthma and 
diabetes were especially increased, and rates and costs for individuals with ≥2 
at-risk conditions approached those among persons with high-risk conditions.  
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OBJECTIVES: To optimize decisions on initial fracture treatment it is of interest 
to identify patients at risk for delayed bone union. The current study aimed to 
estimate the impact of smoking on the rate of union of tibia fractures. 
METHODS: A systematic literature search (1990–2012) was performed using the 
Cochrane library, Medline and Embase to identify studies that evaluated  
the effect of smoking on healing of ‘fresh’ tibia fractures. The endpoint of 
interest was the hazard ratio (HR) of bone union between smokers and  
non-smokers. Reported and calculated HRs were pooled applying a Bayesian 
random effects analysis. RESULTS: Six observational studies were identified all 
reporting favorable time to union for non smokers relative to smokers. One study 
was excluded from the meta-analysis as it did not allow for estimating a HR.  
One study reported an adjusted HR, whereas four other studies reported mean or 
median time to union. For these latter studies, HRs were estimated assuming 
constant hazard rates for bone union from week 7 following surgery.  
The analysis demonstrated that the rate of bone union was delayed in smokers 
relative to non-smokers, mean HR: 0.74, 95% credibility Interval (CrI): 0.65-0.85, 
corresponding to a >99% probability of delayed bone union in smokers, with  
a mean (95% CrI) delay of 3.0 (2.9-3.2) weeks. The current analysis has limitations 
which relate mainly to the observational nature of the included studies as  
well as the distributional assumptions required for estimating HRs. A sensitivity 
analysis excluding 1 study reporting the most favorable results for non- 
smoking still indicated a >99% probability of slower bone union in smokers as 
compared to non-smokers. CONCLUSIONS: The current study indicates that 
patients that smoke are at increased risk for delayed healing of tibial fractures 
and an evaluation of initial adjunctive treatment in these patients may be 
merited.  
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There is evidence to suggest that young children with eczema are predisposed  
to developing asthma in their early life and it is proposed that previous eczema 
diagnosis could predict a more severe form of subsequent asthma. Therefore,  
it is vital to consider measures and policies to influence the pathogenesis of this 
disease. OBJECTIVES: To explore whether prescription data can identify those 
eczema patients at greater risk of developing severe asthma as early as possible 
in their atopic disease pathogenesis. METHODS: Using UK prescription data  
from IMS-Disease AnalyzerTM two case-controlled cohorts were extracted and 
analysed. The cohorts consisted of 20,095 and 5,840 patients respectively. 
RESULTS: The odds of a child with eczema having asthma before the age of  
13 were 2.6 times greater (p<0.001; 95% CI 2.5-2.8) than a child who had no 
eczema at the same age. When comparing patients classified as having severe 
eczema, the odds of developing severe asthma before the age of 13 were 1.7 
times greater (p<0.001; 95% CI 1.5-1.9) for children who had eczema before their 
third birthday than those who had no eczema born in the same year.  
The analysis of prescription data were restrictive in the electronic record  
so assumptions and the additional criteria imposed during analysis may have 
introduced bias. CONCLUSIONS: Severity in asthma patients in the UK have  
now come to the forefront of discussion at many levels - patients, health  
care professionals and government. The burden of morbidity of atopic disease 
could be influenced in a downward fashion if greater efforts and resources  
were focused at national level to improve the plight of patients and ensure 
efficient use of the scarce health care resources available. Robust cost-
effectiveness analyses are required to argue the case for expenditure on this 
neglected area.  
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OBJECTIVES: Legislators, health system administrators, employers and other 
stakeholders are increasingly concerned about growing health care costs. 
Technologies must therefore continue to demonstrate safety and effectiveness 
alongside sound economics. Surgical tools for balloon catheter dilation (BCD) of 
sinus ostia offer an alternative way for surgeons to treat patients with chronic 
rhinosinusitis (CRS) in a tissue-sparing fashion. In some instances, these tools 
are also used alongside rigid instruments during functional endoscopic sinus 
surgery (FESS). BCD has strong safety and effectiveness evidence and allows 
migration of site of care from the operating room (OR) to the physician office. 
However, limited data exist analyzing the economic impact of the technology on 
CRS cost of care. METHODS: A budget impact analysis (BIA) was developed to 
determine the potential impact of BCD on health care costs. The analysis was 
performed from the viewpoint of the US payer and actual payments for health 
care services were included in the model, in lieu of costs. Inputs included 
frequency of service and payments for preoperative care and surgery; frequency, 
type of visits and procedures and payments for postoperative care (including 
debridements and related procedures), and payments and frequency of 
reoperations and exacerbations. Clinical inputs were based on published 
literature and analyses of claims databases from Marketscan, using a cohort with 
at least 2 years of continuous enrollment post-index. Monte Carlo simulations 
were conducted to determine impact of uncertainty on final estimates. RESULTS: 
For 1,400 surgical cases (expected surgical volume within a 1 million population), 
the total cost of care over 2 years assuming current treatments was estimated at 
US$ 14.23±0.26 million. Assuming however that 20% patients transition from 
FESS to BCD and 10% thereof would be treated in the office versus the OR, total 
cost would reach US$13.92±0.22 million. CONCLUSIONS: For well selected 
patients, shifting site of care from the OR to the office, along with the less-
invasive BCD technology versus FESS, shows trends of cost favorability over a 2-
year time horizon.  
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